5th Annual Cell Engager Summit Hilton Boston Logan Airport, Boston

The TCE pipeline is ever-growing and there are multiple different formats, engagers and costimulatory being studied in over 90 trials, with over a hundred projects in the preclinical stage. To treat hematological malignancies, the majority of pharmaceutical and biotech companies are focusing on lymphocyte-restricted tumor-associated antigens such as CD19, CD20, BCMA, CD33, and CD123.

The 5th Annual Cell Engager Summit will discover everything there is to know about the immune cell engager landscape, including clinical successes, prospective response predictors, and cutting-edge immune cell-based engager therapeutic discoveries. To increase safety (lower CRS) and efficacy (higher dose, better tumor penetration/accumulation, lower TMDD) in the solid tumor microenvironment, target tumor antigens (HER2, EGFR, etc.) and change co-stimulatory receptors (CD137/4-1BB, CD28). Use properly proven strategies to address effectiveness issues such as T-cell depletion in solid tumors (alternatives to CD3s, maybe NK engagers), toxicity in hematological malignancies (protease/ph-based cleavage), and toxicity in hematological tumors.

24 Apr - 27 Apr 2023, 8:00 am - 5:00 pm

Go to Event Website
Ticket pricing starts from:
Conference + Pre-Conference Day - Drug Developer Rate: USD 4297.00, Conference Only - Drug Developer Rate: USD 2999.00, Conference + Pre-Conference Day - Academic Rate: USD 3697.00, Conference Only - Academic Rate: USD 2599.00, Conference + Pre-Conference Day - Solution Provider Rate: USD 5297.00, Conference Only - Solution Provider Rate: USD 3799.00